Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society.
Authors
van de Laarschot, Denise MMcKenna, Malachi J
Abrahamsen, Bo
Langdahl, Bente
Cohen-Solal, Martine
Guañabens, Núria
Eastell, Richard
Ralston, Stuart H
Zillikens, M Carola
Keywords
anabolicsantiresorptives
osteoporosis
Metadata
Show full item recordJournal
The Journal of clinical endocrinology and metabolismDOI
10.1210/clinem/dgz295PubMed ID
31867670Abstract
Context: Atypical femur fractures (AFFs) are serious adverse events associated with bisphosphonates and often show poor healing. Evidence acquisition: We performed a systematic review to evaluate effects of teriparatide, raloxifene, and denosumab on healing and occurrence of AFF. Evidence synthesis: We retrieved 910 references and reviewed 67 papers, including 31 case reports, 9 retrospective and 3 prospective studies on teriparatide. There were no RCTs. We pooled data on fracture union (n = 98 AFFs on teriparatide) and found that radiological healing occurred within 6 months of teriparatide in 13 of 30 (43%) conservatively managed incomplete AFFs, 9 of 10 (90%) incomplete AFFs with surgical intervention, and 44 of 58 (75%) complete AFFs. In 9 of 30 (30%) nonoperated incomplete AFFs, no union was achieved after 12 months and 4 (13%) fractures became complete on teriparatide. Eight patients had new AFFs during or after teriparatide. AFF on denosumab was reported in 22 patients, including 11 patients treated for bone metastases and 8 without bisphosphonate exposure. Denosumab after AFF was associated with recurrent incomplete AFFs in 1 patient and 2 patients of contralateral complete AFF. Eight patients had used raloxifene before AFF occurred, including 1 bisphosphonate-naïve patient. Conclusions: There is no evidence-based indication in patients with AFF for teriparatide apart from reducing the risk of typical fragility fractures, although observational data suggest that teriparatide might result in faster healing of surgically treated AFFs. Awaiting further evidence, we formulate recommendations for treatment after an AFF based on expert opinion.Item Type
ArticleOther
Language
enEISSN
1945-7197ae974a485f413a2113503eed53cd6c53
10.1210/clinem/dgz295
Scopus Count
Collections
Related articles
- Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide.
- Authors: Miyakoshi N, Aizawa T, Sasaki S, Ando S, Maekawa S, Aonuma H, Tsuchie H, Sasaki H, Kasukawa Y, Shimada Y
- Issue date: 2015 Sep
- Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures.
- Authors: Starr J, Tay YKD, Shane E
- Issue date: 2018 Aug
- Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
- Authors: Davis S, Simpson E, Hamilton J, James MM, Rawdin A, Wong R, Goka E, Gittoes N, Selby P
- Issue date: 2020 Jun
- The effects of teriparatide on acceleration of bone healing following atypical femoral fracture: comparison between daily and weekly administration.
- Authors: Tsuchie H, Miyakoshi N, Iba K, Kasukawa Y, Nozaka K, Dohke T, Kosukegawa I, Aizawa T, Maekawa S, Abe H, Takeshima M, Tomite T, Segawa T, Ouchi K, Kinoshita H, Suzuki M, Yamashita T, Shimada Y
- Issue date: 2018 Dec
- Different surgical outcomes in a patient with bilateral atypical femoral fracture related to bisphosphonate use with or without teriparatide treatment.
- Authors: Zhang HY, Weng HL, Li M, Zhang J
- Issue date: 2019 Nov